N4 Pharma PLC Change of Adviser (9917S)
15 Julio 2020 - 1:00AM
UK Regulatory
TIDMN4P
RNS Number : 9917S
N4 Pharma PLC
15 July 2020
15 July 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Change of Adviser
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce the appointment of SP Angel
Corporate Finance LLP as the Company's Nominated Adviser and Joint
Broker, with immediate effect.
Management Change
The Company also announces that Luke Cairns, previously a
Non-Executive Director of the Company, has been appointed to an
Executive Director position. Luke will be overseeing the Company's
finance and investor relations activities, thereby allowing Nigel
Theobald, Chief Executive Officer, more time to focus on driving
the Company's development programmes and potential commercial
collaborations.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via Scott PR
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
Scott PR
Georgia Smith Tel: +44(0)1477 539
539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPRIMITMTJBBMM
(END) Dow Jones Newswires
July 15, 2020 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024